Home 禄 Business 禄 Manufacturing
Novartis swoops on new heart drug
Source: Agencies |
December 24, 2009, Thursday
|
Print Edition
Print Edition
SWISS pharmaceuticals maker Novartis AG said yesterday it would buy United States biopharmaceutical company Corthera Inc for US$120 million, giving it the right to develop a new drug against heart failure.
The acquisition of Corthera is subject to regulatory approval and should be completed by the end of next year, Novartis said.
The privately owned company has been developing relaxin, which is in the third trial phase as a potential treatment for patients with acute heart failure, Novartis said.
Novartis said it would be responsible for completing the development of relaxin and planned to submit requests to put it on the market in the United States and Europe in 2013.
Shares in Novartis were down 0.09 percent at 56.80 Swiss francs (US$54.25) on the Zurich exchange yesterday.
The acquisition of Corthera is subject to regulatory approval and should be completed by the end of next year, Novartis said.
The privately owned company has been developing relaxin, which is in the third trial phase as a potential treatment for patients with acute heart failure, Novartis said.
Novartis said it would be responsible for completing the development of relaxin and planned to submit requests to put it on the market in the United States and Europe in 2013.
Shares in Novartis were down 0.09 percent at 56.80 Swiss francs (US$54.25) on the Zurich exchange yesterday.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
